News Sumitomo Pharma Co., Ltd.

Stocks

4506

JP3495000006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-07-13 am EDT			5-day change	1st Jan Change
1,342.00 ^JPY	-4.14%		-13.81%	-42.11%

Jul. 10	Citi Upgrades Sumitomo Pharma to Neutral from Sell; Price Target is 1,500 Yen	MT
Jun. 21	Sumitomo Pharma Co., Ltd.(TSE:4506) added to S&P Japan 500	CI

All News

Mentions Relevance

Jul. 10	Citi Upgrades Sumitomo Pharma to Neutral from Sell; Price Target is 1,500 Yen	MT
Jun. 21	Sumitomo Pharma Co., Ltd.(TSE:4506) added to S&P Japan 500	CI
Jun. 04	Sumitomo Pharma Co., Ltd., 2026 Earnings Call, May 13, 2026
Jun. 01	Sumitomo Pharma : America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026	PU
May. 31	Sumitomo Pharma : Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change	PU
May. 22	Sumitomo Pharma Co: SMBC Nikko Securities notified it will not subscribe for any shares, accordingly issuance of new shares by way of third-party allotment will not be implemented	RE
May. 15	Sumitomo Pharma : May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）	PU
May. 15	Sumitomo Pharma : Posted Conference on FY2025 Financial Results	PU
May. 13	Sumitomo Pharma : May 13, 2026 Conference on FY2025 Financial Results（PDF/1,054KB）	PU
May. 13	Sumitomo Pharma : Presentation Material (Conference on FY2025 Financial Results )	PU
May. 13	Sumitomo Pharma : Announces Personnel Changes	PU
May. 13	Sumitomo Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
Apr. 26	Sumitomo Pharma Co Ltd - Notice regarding withdrawal of shelf registration statement for issuance of new shares	RE
Apr. 20	Sumitomo Pharma Co Ltd - Notice regarding determination of issue price, selling price and other matters	RE
Apr. 09	Sumitomo Targets 116.5 Billion Yen via Share Issuance, Secondary Offering	MT
Apr. 08	Sumitomo Pharma to Launch Global Offering of Up to 59 Million Shares	MT
Apr. 08	Sumitomo Pharma to Refinance Borrowings through Bridge Loan	MT
Apr. 08	Sumitomo Pharma Co Ltd - Will conduct new share offering	RE
Apr. 08	Sumitomo Pharma Co Ltd - To refinance existing borrowings through a bridge loan	RE
Apr. 08	Sumitomo Pharma Co Ltd - Will conduct secondary share offering	RE
Mar. 30	Sumitomo Pharma : Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia	PU
Mar. 25	Sumitomo Pharma to Book 48.3 Billion Yen in Non-Operating Income	MT
Mar. 23	Sumitomo Pharma America announces that its investigational therapy DSP-3077 has received FDA Orphan Drug Designation for the treatment of retinitis pigmentosa	RE
Mar. 09	Sumitomo Pharma Co., Ltd. - Special Call
Mar. 05	Sumitomo Pharma Secures iPS Cell Therapy Approval for Parkinson's	MT